← TrialMatch
HomeTrials

Language and Lewy Body Diseases: Sentence Comprehension Problems and Modifying Noninvasive

Lewy body diseases (LBDs) represents a group of neurodegenerative disorders characterized by the abnormal accumulation of aggregates of α-synuclein protein leading to the formation of Lewy bodies (LB) and Lewy neurites resulting in cell death. LBDs consists of two major clinical entities - Parkinson's disease (PD) and

Condition(s)Lewy Body Disease, Healthy Aging
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryLewy body diseases (LBDs) represents a group of neurodegenerative disorders characterized by the abnormal accumulation of aggregates of α-synuclein protein leading to the formation of Lewy bodies (LB) and Lewy neurites resulting in cell death. LBDs consists of two major clinical entities - Parkinson's disease (PD) and dementia with LB (DLB). Vast majority of patients with LBDs either already have mild cognitive impairment (MCI) at the time of the diagnosis or will develop it during the course of the disease. Language dysfunctions in LBDs patients with MCI are often unrecognized, which are difficult to treat, but even subtle changes might lead to impairment of social and occupational functioning with profound effect on their quality of lives. Current pharmacological or surgical strategies a
Who can participateInclusion Criteria: * right-handedness * Czech as their first language * age (60-80 years) * presence of PD-MCI (Litvan et al. 2012) or MCI-LB (McKeith et al. 2020) for LBD subjects Exclusion Criteria: * cardio pacemaker * any MRI-incompatible metal in the body * epilepsy * any diagnosed psychiatric disorders * alcohol/drug abuse * for HC group the presence of LBDs or other neurodegenerative disorder or MCI/dementia
Ages60 Years to 80 Years
SexAll
Accepts healthy volunteersYes
Lead sponsorMasaryk University
LocationsBrno, Czechia
Start date2023-05-01
NCT IDNCT05847985
Official listinghttps://clinicaltrials.gov/study/NCT05847985

🔍 Search all trials →